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In this paper, we review the results of BIOINFOMED, a study funded by the European Commission (EC) with the purpose to
analyse the diﬀerent issues and challenges in the area where Medical Informatics and Bioinformatics meet. Traditionally, Medical
Informatics has been focused on the intersection between computer science and clinical medicine, whereas Bioinformatics have been
predominantly centered on the intersection between computer science and biological research. Although researchers from both areas
have occasionally collaborated, their training, objectives and interests have been quite diﬀerent. The results of the Human Genome
and related projects have attracted the interest of many professionals, and introduced new challenges that will transform biomedical
research and health care. A characteristic of the post genomic era will be to correlate essential genotypic information with expressed* Corresponding author. Fax: +34-91-509-79-17.
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F. Martin-Sanchez et al. / Journal of Biomedical Informatics 37 (2004) 30–42 31phenotypic information. In this context, Biomedical Informatics (BMI) has emerged to describe the technology that brings both
disciplines (BI and MI) together to support genomic medicine. In recognition of the dynamic nature of BMI, institutions such as the
EC have launched several initiatives in support of a research agenda, including the BIOINFOMED study.
 2003 Elsevier Inc. All rights reserved.
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The Human Genome has created new opportunities
for the study of monogenic and complex, more prevalent,
multigenic diseases [1]. Increased knowledge of the hu-
man genome supports the theory that diseases should be
understood by considering the complex interactions be-
tween genes and environmental factors that initiate
pathological processes and deﬁne the phenotype [2,3].
The large amounts of genetic and proteomic data [4] oﬀer
opportunities for new research targets and biomedical
applications. New therapies for established diseases and
novel interventions for preventing diseases are being de-
veloped and discussed [5]. These innovative approaches
cannot be sustained without eﬀectively dealing with the
vast amounts of data generated in the laboratory in the
areas of functional and structural genomics and proteo-
mics (the world of BI) [6]. Within this framework, it is
equally important to integrate clinical data generated by
medical records (the world ofMI) [7]. Such an integration
will lead to innovative approaches to link patient care and
public health. In such an environment, data-centered
electronic health records (EHR), clinical decision support
systems, and image and signal processing techniques and
tools can be applied to a broader ﬁeld of information.
Biomedical Informatics (BMI) is the emerging discipline
that aims to create this common conceptual information
space to further the discovery of novel diagnostic and
therapeutic methods in the rapidly evolving arena of ge-
nomic medicine.
The need for integrated post-genomic approaches in
medicine has been aptly stated by the World Health
Organization:
Some of the claims for the medical beneﬁts of genomics have un-
doubtedly been exaggerated, particularly with respect to the time
scales required for them to come to fruition. Because these uncer-
tainties, it is vital that genomics research is not pursued to the det-
riment of well-established methods of clinical practices, and
clinical and epidemiological research. Indeed, for its full exploita-
tion it will need to be integrated into clinical research involving
patients and into epidemiological studies in the community. It is
crucially important that a balance is maintained in medical prac-
tice and research between genomics and these more conventional
and well tried approaches. [8].2. Motivation
The Conference Synergy between Research in Med-
ical Informatics, Bioinformatics, and Neuroinformatics(Brussels, December 14, 2001, http://www.ramit.be) was
the kick-oﬀ point for a series of European-centered ac-
tivities related to the analysis of the current status and
interactions between MI and BI. After various meetings
and discussions, a study named BIOINFOMED (http://
bioinfomed.isciii.es/) (‘‘Prospective Analysis of the Re-
lationships and Synergy Between Medical Informatics and
Bioinformatics’’) [9] was approved and launched with
support from the European Commission (http://
www.cordis.lu/ist/) in March, 2002. It was aimed to
analyse the relationships and potential synergies be-
tween MI and BI. Several goals were set for the project,
including the elaboration of a White Paper, which
should provide a number of clues for the European
Commission itself and for researchers and professionals
from these and other related areas.
Three groups, at the Institute of Health Carlos III
(ISCIII) (http://www.isciii.es/) (Madrid), at the Poly-
technical University of Madrid (http://www.dia.-
ﬁ.upm.es/) and at the University of Link€oping (http://
www.liu.se/en/), were the main contractors of the BIO-
INFOMED study. Thirty professionals from various
European and US organizations were invited to partic-
ipate and provide their expertise and knowledge. Ex-
perts from disciplines such as MI, BI, genomics, public
health, clinical medicine, and bioengineering covered a
wide range of interests and areas.
At the start of the study, a questionnaire was elabo-
rated by the team at the ISCIII, including questions on the
status and future of MI and BI, research directions, and
the potential of already existing tools and methodologies
that could be transferred between both disciplines and
then be reused in BMI projects and topics. Responses
were processed andapreliminarydocumentwasmailed to
the experts. Two meetings took place in 2002, in Crete
(Greece) and Valencia (http://bioinfomed.isciii.es/Bio-
inforsalud2002/Bioinforsalud2002–en.htm) (Spain), where
experts discussed the contents of the document extensively.
A draft for the White Paper was made and later reﬁned
and completed over the Internet by all participants.
This paper includes an abridged version of the ﬁnal
White Paper (http://bioinfomed.isciii.es/Bioinfomed/The
White Paper/results/White Paper.pdf) delivered to the
European Commission [10]. The paper is divided in
various sections: (1) Background, (2) Expected impact,
(3) Gaps and bridges, (4) Collaborative R&D agenda for
BI and MI, and (5) Conclusions. Further details of the
sections can be found below.
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MI and BI are two interdisciplinary areas located at
the intersection of informatics with medicine and biol-
ogy (genomics), respectively. Historically, MI and BI
have always been separated and only occasionally have
researchers of both disciplines collaborated in the past
[11]. Almost from its very beginning MI focused mainly
on the development of practical computer applications
for health purposes. Recently, a debate has been initi-
ated on its scientiﬁc content and future. BI, a younger
discipline, has grown enormously due to its contribution
to genomic research [12].
MI has traditionally been focused on the develop-
ment of computer applications for representing and
implementing health care [13]. As health care moves
from patient/hospital-centered systems to citizen/com-
munity-centered systems, genetic data should be in-
creasingly available for patient care, driving MI in a
direction where synergy with BI could be naturally
achieved [14,15]. BI has evolved to handle large amounts
of sequence and structural data, generated in the labo-
ratory [16]. While BIs success in handling large data
volumes is apparent, its weakness in data normalization
will continue to cause problems for collaborative
research.
When considering public-health issues, reasons for
synergy become more compelling, and various reasons
arise for interactions among epidemiology, clinical
research and genomics.
Increasing awareness of BMI is evidenced by recent
conferences [17–19]. For instance, the American Medi-
cal Informatics Association (AMIA) (http://www.
amia.org/) has focused on the interaction between BI
and MI at recent meetings. Panels, tutorials and sessions
in periodic congresses (MEDINFO, MIE, PSB, RE-
COMB, ISMB, and ECCB) highlight this awareness,
which has also been shown by various special issues
published at diﬀerent scientiﬁc journals. Other key ac-
tivities include the inclusion of BI in university medical
training programs [20] and collaboration with the
pharmaceutical industry for physician training and
technical support in genomics.4. Expected impact
The biomedical community seeks to remove the walls
between biological information and medical informa-
tion. The interoperability of biological and medical in-
formation for all appropriately authorized users creates
imperatives, opportunities, and challenges. Equally sig-
niﬁcant demands are made by the evolution from pa-
tient-centered systems to citizen-centered systems that
actively engage citizen participation. The impact can be
seen in various categories, such as:4.1. Scientists/researchers
There is an implicit requirement for exchanging and
sharing medical and biological information and knowl-
edge in global (often virtual) work settings. Equally
important is that professionals with background in ei-
ther medical informatics or bioinformatics are better
able to understand the basic principles and interrelations
of all disciplines involved (the same requirement also
applies to clinical health personnel who need to expand
their background knowledge of pertinent topics).
4.2. Clinical trials
New clinical trials must be carefully designed to in-
clude genomic and proteomic data. High-quality bio-
medical databases are urgently needed to provide a
sound scientiﬁc basis for diagnostic, treatment stratiﬁ-
cation and predictive tests. Ethical, legal, and privacy
considerations should be given to tests that evoke anx-
iety in healthy people regarding their future [21].
4.3. Health-care professionals
4.3.1. New knowledge and technology
The very nature of BMI blurs some of the classical
distinctions between clinical and molecular information.
As we extend the concept of phenotype to encompass
diseases, we also expand the properties that are visible
to include sub-cellular structures and physiological
processes. One of the major impacts of BMI will be a
broader understanding of how combinatorial and
quantitative variations in DNA sequences, protein syn-
thesis, and subsequent protein function aﬀect the evo-
lution of diseases. Genomic and proteomic data analysis
has already facilitated both the understanding of the
underlying causes of the disease and the identiﬁcation of
new drug targets. As our knowledge about the molecu-
lar causes of disease increases, we can expect more ele-
gant molecular interventions to diagnose, disrupt or
ameliorate disease.
4.4. Individual citizens
4.4.1. The citizen ‘at risk’
New BMI approaches can give new dimensions to the
concept of citizen-at-risk. As the basis of the knowledge
on genetic associations with illnesses increases, it is
likely that this identiﬁable ‘‘at risk’’ group will grow,
encompassing many asymptomatic citizens and there-
fore placing new demands on health-care systems.
4.4.2. Informed citizens
It will be important for health delivery systems to
establish and publish standards for rational genetic
testing. The average citizen must be able to understand
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tential for health improvement and the potential draw-
backs that could arise from such testing.
4.5. Health-care providers and systems
4.5.1. Technology diﬀusion and scientiﬁc evidence
With the emergence of novel BMI applications,
health-care systems will face diﬃcult challenges. Health-
care providers should be prepared to carefully select
technologies that have been proven safe and eﬀective. If
required, providers should limit the adoption of new
technologies to appropriate scientiﬁc research settings.
4.5.2. Public health and disease prevention
Knowledge generated by very large biomedical da-
tabases will enable health-care organizations to identify
citizens who are not only at genetic risk for developing
diseases but also whose risk of developing symptomatic
disease could be reduced by one or more interventions.
4.6. Policy-decision makers
4.6.1. Investment for the future
Rational biomedical databases of the scope required
for modern molecular research are expensive to establish
and maintain. Programmed cooperation between gov-
ernment, academia and the industry is absolutely
essential.
4.6.2. Prioritisation
Genetic testing and the associated concept of citizen-
at-risk will constitute yet another aspect to the current
prioritization palette.
4.6.3. Legislative initiatives
Novel biomedical informatics applications will re-
quire clear and up-to-date legislation. Policy makers will
have to foster a proactive and continuous legislative
process that will keep up with the pace of current sci-
entiﬁc developments and implementation plans. Such
attempts have resulted in pertinent legislation in some
countries (e.g., the Estonian Human Genes Research
Act of 2000 (http://www.geenivaramu.ee/).
4.7. Industry
In order for certain industrial eﬀorts to succeed (such
as pharmaceutical and biotechnology), more attention
will have to be paid to how both clinical trials and ex-
ploratory analyses evolve and become successful. In-
dustries taking advantage of the development and
maintenance of large databases and knowledge bases by
academic institutions should contribute to the ﬁnancing
of such public initiatives and collaborative eﬀorts among
diﬀerent institutions.4.8. Society
4.8.1. Consent to collect, view, and use information
Genomic and proteomic databases must be secured
from unwanted intrusions. Correlation between clinical
and genomic/proteomic proﬁles should only take place
when informed consent has been obtained. Every citi-
zens right to not know about his/her genetic risk should
be respected.
4.8.2. Genetic discrimination
Scenarios of selection or exclusion on the basis of
individuals genetic proﬁles are not acceptable, and this
fundamental principle should be guaranteed through
pertinent legislation.
4.8.3. Racial proﬁling
Already, scientists are engaged in debates about eth-
nicity versus race, and one can see how genetic assess-
ments of this sort are invitations for misusing large
biomedical databases. Great care must be taken to
guarantee that biomedical databases are not subjected
to unauthorized analyses of this sort.
4.8.4. Fetal testing and pregnancy termination
At the present time, pregnant women may elect to
have their pregnancy terminated as a result of genetic
testing of the fetus. As the knowledge about genotypes
at risk for disease increases, more couples will be faced
with the decision whether or not to have the fetus tested,
and whether to act on the results of such testing.
Above we have stated some of the consequences that
can result from the introduction of genomic information
in various aspects of medicine. Numerous challenges can
be envisioned for MI and BI, including some issues that
must be analyzed and solved, as will be shown below.5. Gaps and bridging solutions
5.1. Gaps
The tools and applications developed by MI reach a
wide range of users including physicians, nurses, ad-
ministrators, management, and researchers [22]. BI
applications are characterized by a much more homo-
geneous user group dominated by researchers. Although
the application domains diﬀer, both MI and BI often use
similar methodologies [23]. Both ﬁelds are active in
machine learning, natural language processing, image
analysis or database research. However, working on
similar problems with related methods does not guar-
antee similar results because the application domains
diﬀer.
Another diﬀerence between the MI community and
the BI community involves the degree of interaction
1 Proteotype: the total of all the proteins that are expressed within
a cell, tissue or organism; by analogy with phenotype for physical,
visible characteristics and genotype for the total of all the genes.
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have been relatively scarce. In BI, collaborative research
has been a key issue for success. This diﬀerence in
sharing and exchanging research results has led to a
signiﬁcant number of open-source programs and infor-
mation resources in BI, whereas eﬀorts in MI have often
been local and private.
The diﬀerent application domains are also reﬂected in
education. The typical MI trainee gets his/her education
in a medical setting (often a medical school), whereas the
focus in BI is in biology. Cognitive reasoning, teaching,
terminologies, research environments, social circum-
stances, and other characteristics are diﬀerent in medi-
cine and biology, imposing some restrictions for
integrated approaches.
5.2. Bridging solutions
Medicine beneﬁts already from the achievements of
biological research [24], whereas biology will beneﬁt
from the use of clinical data for research [25]. As the
domains begin to overlap, both communities will in-
creasingly explore additional interactions. Examples
include, among others, the development of ontologies
and taxonomies, the use of natural language processing
and information retrieval.
Collaboration is driven by two principal factors.
First, the results of research in molecular biology will
increasingly move towards clinical research and clinical
practice [26]. Second, the methodologies used by BI and
MI will prove to have many similarities, allowing ex-
change of experience between the two ﬁelds. Finally, we
should appreciate the changes that biomedical science in
general is experiencing. There is a transition from a
period of data starvation to a period of data overload—
both in terms of research and patient data. We are
standing on the threshold of a new era: we need com-
puters not only to store the data we collect, but also to
verify and expand the interpretations we are construct-
ing. We suggest that future initiatives should fall into
three categories: (1) stimulating integration at the in-
formational exchange level, (2) initiating collaborations
between the communities, and (3) training a new gen-
eration of scientists that speak both languages.
The proposed research agenda outlines the strategies
and solutions coming from three diﬀerent points of view
or directions based on the ﬂow of data and information.
They are: (1) what can MI contribute to functional ge-
nomics, (2) what can BI contribute to individualized
health care, and (3) how can the new area of BMI, in-
cluding new combined approaches, contribute to geno-
mic medicine. All these directions require the
advancement of the enabling technologies necessary for
the development of the solutions proposed in each of the
above-mentioned areas. Fig. 1 shows a graphical rep-
resentation of these diﬀerent perspectives.6. Collaborative agenda for BI and MI
Eighteen research lines have been identiﬁed and are
grouped in various categories, as shown below.
6.1. MI in support of functional genomics
Genomic researchers are working to discover the mo-
lecular mechanisms of diseases. Access to and integration
of data coming from the clinical setting is essential for
functional genomics research. MI professionals need to
accelerate the development of both the information
models and the tools needed for these tasks.
(1) ‘Phenotype’ databases for clinical annotation of bi-
ological samples and for clinical validation of biological
research results. To generate new knowledge from geno-
mic and proteomic data, we need to combine the pheno-
types, genotypes and proteotypes1 of very large numbers
of patients, ideally from diﬀerent parts of the world [27].
The medical community needs to adapt standardized
annotations for biological samples, and to develop labo-
ratory procedures that will facilitate comparison of ge-
nomic and proteomic test results [28].When all data types
of patient characteristics (phenotype, genotype and pro-
teotype) are represented in a standardized, structured
format, wewill be able to realize the value of new genome-
based technologies and to apply these techniques for the
beneﬁt of individual patients [29,30].
(2) Disease reclassiﬁcation. The classiﬁcation of dis-
eases can now be reorganized, beginning at a molecular
level, by using new insights in pathophysiology derived
from functional genomics [31]. As mentioned above, the
integration of complex databases from MI (clinical in-
formation) with those from BI (genome data) is required
to validate functional genomic research [32]. For this
validation process, issues such as data quality, appro-
priate sample sizes and common data models must be
addressed [33].
(3) Informatics for supporting rational drug design
and development. Post-genomic techniques and tools
are already integrated into some of the key steps of the
drug-development pipeline, including target identiﬁca-
tion and validation, lead compound ﬁnding and opti-
mization, toxicity studies [34], patient typing and
stratiﬁcation for clinical phases [35]. The implementa-
tion of these new technologies is expected to increase
eﬃciency, thereby reducing time to market and, ulti-
mately, cost [36].
Even with more than 10,000 potential targets, the
opportunity to dramatically transform the drug-dis-
covery process through a combined in silico and lead
compound development pipeline has so far been
Fig. 1. A picture reﬂecting the viewpoints expressed in this paper. It reﬂects the interdisciplinarity of both MI and BI as well as of the new emerging
disciplines of Genomic Medicine and the core of BMI. The arrows show the diﬀerent perspectives related to potential synergies among the above-
described areas.
Fig. 2. Representation of current and future technological developments in MI and BI.
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BI/cheminformatics and protein/DNA microarray
technology with MI in studies of preclinical and clinical
toxicity as well as of patient typing and stratiﬁcation.
6.2. BI in support of individualized health care
(4) Including genetic data in the electronic health re-
cord. Electronic health records (EHR) are being in-
creasingly used by practitioners for routine patient care;
they contain an increasing amount of coded, structured
data. Although genetic data are beginning to be in-
cluded in EHRs, current records have not been designed
to include speciﬁc requirements for representing genetic
data [37]. As a result, genetic data are typically recorded
as laboratory data. Consequently, the use of the data is
limited (e.g., family relationships are often recorded
only minimally, limiting the possibilities for studying
relationships among the phenotypes of relatives) [38]. If
we expect to use genetic data in health care, models need
to be developed that will support the optimal entry of
and access to such data in electronic health records.
(5) Methods for personalized health care: guidelines
and decision-making support systems. Clinical guidelines
are standard means for disseminating clinical knowledge
to support physicians in decision-making processes.
Clinical guidelines are represented in diﬀerent ways, e.g.,
as text documents (in paper or electronic form) or using
speciﬁcations such as Guideline Interchange Format
(GLIF) [39]. In all cases, guidelines incorporate various
sorts of expert, professional recommendations for the
diagnosis, treatment and prevention of particular dis-
eases. An example of a guideline-based decision support
is EON (http://smi-web.stanford.edu/projects/eon/) [40]
or DIADOQ [41]. Using genetic information can further
enrich the quality of clinical decision-making [42].
(6) Telegenetics. Telemedicine is already being em-
ployed to deliver a number of genetic medicine services
[43]. Telemedicine-enhanced services are being used by
centers specializing in cancer genetics, clinical genetics,
and reproductive genetics [44]. Many genetic centers
that routinely use phone consultations with physicians
and phone interactions with patients to help determine
the need for genetic services or to prepare for an ap-
pointment are moving to Internet-based services that
incorporate all of the requirements for security and
conﬁdentiality [45,46]. For genetic counsellors and
medical geneticists, telemedicine has developed powerful
tools that unite various kinds of distributed information:
personal and family history, physical ﬁndings, and ra-
diology and pathology results [47].
(7) Stratifying patients by their genetic proﬁles: mo-
lecular diagnosis, clinical trials, and pharmacogenomics.
One of the beneﬁts of the study of the human genome is
the identiﬁcation of the SNPs and haplotypes present in
the human population. With this information, stratiﬁ-cation of people based on their genetic proﬁle will in-
crease the knowledge regarding interactions between the
environment and genetic traits and how such interac-
tions aﬀect the development of diseases [48]. Informa-
tion on the diﬀerent genotypes together with phenotypic
and environmental information will allow us to improve
the design of clinical trials and to optimize treatments
[49]. Such new therapeutic approaches will blur the
boundaries between diagnosis and pharmacology, lead-
ing to the potential for more personalized medicine
[50]. A robust BMI infrastructure is needed for the in-
tegration of genetic and environmental data into clinical
studies (clinical trials), and for the design of personal-
ized therapeutic interventions based on additional
stratiﬁcation information.
(8) Point-of-care data collection and access. At pres-
ent, genetic data are only being collected by major
clinical research laboratories. New DNA/protein detec-
tion technologies are developing rapidly (e.g., biochips
or lab-on-a-chip) and these technologies will not require
complex laboratory environments to perform sophisti-
cated tests. These new analytical devices will enable us to
establish patients genetic proﬁles within a reasonable
time (and at reasonable expense) at the point-of-care
[51]. Such advances will generate signiﬁcant challenges
for data processing, handling, communication, security
and storage [52]. Proper use of these data will require
additional medical education and training.
(9) Complexity in characterizing genomic and pheno-
typic microbial diversity related to infectious diseases
(Microbial genomics). Microbial genomics require
whole-genome sequencing coupled with BI tools to fa-
cilitate assembly, gene prediction, and functional
annotation. This approach has revolutionized our un-
derstanding of the biology of important human micro-
bial pathogens [53]. Comparative genome analysis
provides insights into adaptations of microbes to their
ecological niches and allows the detection of factors that
shape host–pathogen interactions [54]. There is consid-
erable evidence that genetic polymorphism in both the
microbial pathogen and host can aﬀect both microbial
virulence and host immune responses to infection. The
elucidation of microbial pathogen genomes will con-
tribute to the characterization of genomic and pheno-
typic microbial diversity as it relates to infectious
diseases, will allow the rapid identiﬁcation of microbial
pathogens by means of genetic markers, and will shed
light on the mechanisms of pathogenicity and antibiotic
resistance [55].
6.3. Biomedical informatics in support of genomic
medicine
Biomedical informatics will stimulate new approaches
to diseases and health, in which all levels of information
(from the molecule to the population, going through the
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itself) will be integrated and processed. Techniques and
methods may be variably applied, depending on the
nature of the problem being addressed. Some method-
ology will come from BI and some from MI, including
public health and epidemiology informatics.
(10) Molecular and functional imaging. Molecular
imaging facilitates the characterization and measure-
ment of biological processes in living animals—including
humans—at tissue, cellular, and molecular levels [56].
Molecular imaging will continue to build on existing
technologies in positron emission tomography (PET),
computerized X-ray tomography (CT), high-ﬁeld mag-
netic resonance (MR) and MR spectroscopy, optical
imaging, and image analysis [57]. Signiﬁcant informatics
tools are needed to support molecular imaging. These
fall into two types:
• Understanding correlations—biostatistics and ma-
chine learning to identify signiﬁcant imaging, geno-
mic, and clinical factors that can help answer
clinical questions and make clinical predictions.
• Elucidating molecular disease pathology—integrated
genomic and protein-interaction databases, pathway
elucidation, analysis, modelling and simulation, and
prediction [58].
While the bulk of molecular imaging research funding
is currently focused on cancer, we foresee opportunities
in cardiovascular disease as well as in neurological dis-
eases such as Alzheimers.
(11) Modelling and simulation for an approach that
integrates physiology and pathology. The discovery and
evaluation of diagnostic and therapeutic agents will be
accelerated and made less costly through the creation
and use of integrated dynamic models of processes
taking place in cells and tissues. These in silico models
will combine, unify and reconcile genomic and proteo-
mic data for better understanding of complex diseases
that involve many molecular species and many cellular
states. BI and MI professionals can make major con-
tributions to these modelling and simulation activities.
Such in silico approaches would not have been possible
without results derived from applying theories of non-
linear dynamical systems, recent advances in the mea-
surement of dynamic processes in individual living cells,
and characterizations of physical properties of biologi-
cal objects. The characterizations range from the elas-
ticity of DNA to mechanical properties of cells and
tissues in diﬀerent physio-pathological situations [59].
Models can be built by combining two complementary
approaches: (1) top-down, from clinical manifestations
to inner mechanisms, and (2) bottom-up, from mole-
cules to clinical manifestations [60]. Only formal models
can provide a uniﬁed abstraction for dealing with the
inherent multi-scalar, complexity, non-linearity, and
self-organization of living systems, the diversity of
pathophysiological processes, and the design of optimaldiagnosis and therapy [61]. Development of shared li-
braries of in silico models of molecules, interactions,
pathways, and functions will be needed.
(12) Epidemiology: biobanks and population reposi-
tories. The development of new genetic information
technologies will lead to cost-eﬀective screening (genetic
tests) at a population level. The intersection of genetic
data from such testing with clinical data (such as is held
in electronic health records), environmental data, and
lifestyle data should lead to an elucidation of polyge-
netic disease causality. When these data are included in
population repositories or biobanks, it can be applied to
public health projects such as disease-prevention pro-
grams that can be targeted to at-risk patients identiﬁed
by genetic information. A more accurate assessment of
the cost-eﬃcacy of pharmacogenetics approaches in
health systems will also be possible. Several initiatives in
the US and in Europe have already started. Some ex-
amples are the CDC with the Human Genome Epide-
miology Network (HuGENet) (http://www.cdc.gov/
genomics/hugenet/default.htm) and the National Cancer
Institute in the USA. There is an ongoing project in
Iceland (Decode) (http://www.decode.com/) that links
health records with genealogical and genotypic infor-
mation. Other on-going projects are also being carried
out in the UK (http://www.wellcome.ac.uk/en/1/bio-
venpop.html) and Estonia [62].
(13) New methods for e-learning in genomic-based
medicine. Due to the increasing amount of clinical
knowledge derived from genomic-based medicine, phy-
sicians must update their knowledge of genetics and
genomics [63]. Learning is enhanced when learners
identify their own needs, select their own strategies, and
evaluate their own learning outcomes [64]. Internet-
based informatics tools can facilitate education
regarding the changes in molecular medicine in a non-
disruptive manner, minimizing physicians rejection [65].
The introduction of new learning technologies that
provide open and ﬂexible learning programs will be
crucial for the improvement of doctors skills and
knowledge [66].
6.4. Enabling technologies
(14) Security. Genomic medicine and the associated
interplay between aggregated data and individual data
have given rise to concern with regard to the proper
collection, storage, communication, and processing of
individually identiﬁable sensitive information. Besides
the more traditional security issues dealing with conﬁ-
dentiality, integrity, availability, and accountability,
additional attention should be given in particular to
privacy and identity protection [67,68]. More advanced
privacy enhancing and protecting measures using pri-
vacy enhancing techniques (PETs) need to be deployed.
These techniques become of even more importance
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tive genetic information. Typical examples of privacy-
related issues and techniques are: anonymization,
pseudonymization, data linkage, gauging for direct and
indirect reidentiﬁcation risks in databases and GRID
environments, proxy services, systems for controlled
database dilution, and privacy-enhancing intelligent
software agents [69].
(15) Communication standards—interoperability
among clinical and genetic information systems. Com-
munication between all information layers is necessary
and has to be provided in a trustworthy way [70]. Ser-
vices have to be developed, implemented and main-
tained for communication security and application
security for heterogeneous distributed networks [71].
Interoperability is the prerequisite for communication
and must be addressed in the following areas:
• Data and knowledge (structure, representation, ter-
minology, etc.)
• Technology (architecture, hardware, and topology)
• Presentation of data and knowledge
• Security for systems, health-care professionals and
patients.
(16) Knowledge representation techniques and novel
approaches for the virtual integration of heterogeneous
clinical and genetic databases. Biomedical information at
many diﬀerent sites is now accessible over the Internet.
In order to leverage this increasing pool of data, re-
searchers need novel methods to search and retrieve
information that must be integrated, gathered, classiﬁed,
and interpreted. To integrate distributed databases, two
levels of heterogeneity must be considered: (1) databases
may be located in various platforms, spread over the
Internet, with diﬀerent architectures, operating systems,
and database management systems, and (2) databases
can present diﬀerent conceptual data models and dif-
ferent underlying database schemas [72]. Tools to solve
these problems include standards for exchanging infor-
mation such as XML (http://www.w3.org/XML/) [73,74]
and HL7 (http://www.hl7.org/) as well as standards for
connecting biomedical devices. Standard-based tools
will facilitate the integration of databases in data
warehouses, federated databases or virtual repositories
[75]. Rather than focusing on the unlikely possibility
of the development of a single terminology to cover
all domains, the emphasis should be on semantic map-
ping between terminologies (including clinical and non-
clinical). In this regard, the development of integrated
ontologies will be essential for many research issues in
BMI [76,77].
(17) Data and text-based knowledge discovery. Data
mining is a step in the process of generating knowledge
in databases [78]. It includes techniques for query
databases, on-line analytical processing, and machine-
learning algorithms. In the medical area, many appli-
cations have been created for decision support toaddress issues such as image and signal analysis and
outlining clinical prognoses for patient conditions [79].
In biology, eﬀorts have been centered on research issues
such as the prediction of protein structures and drug
studies [80]. Both types of predictive exercises present
considerable challenges for future research. Text mining
is a discipline that aims to extract data, information or
knowledge from texts [81]. Finding information in bio-
medical databases using text mining and information-
retrieval techniques is expected to leverage a substantial
amount of biomedical information that has escaped
analysis until now.
(18) Grid applications in biomedicine. Linking com-
puters through Grid middleware will enable users to ac-
cess additional computing power to retrieve information
from heterogeneous and distributed sources without
having to choose to which machine he/she wishes to
connect [82]. In the last few years, the term Grid has
evolved to encompass a concept of ubiquitous and
transparent computing. Today, the Grid implies a shared
and coordinated knowledge structure as well as a vision
for intensive computing [83]. Although Grid technology
and standards are still being developed, the vision is to
create a Grid-based environment for both knowledge
discovery as well as for high-performance computing
power. In such an environment, information at various
levels (molecule, cell, tissue, individual, and population)
can be associated to provide personalized health care.
Collaborative eﬀorts leading to the creation of a Health-
GRID (http://www.healthgrid.org/) community that will
provide basic common services (web portals, computing
resources) is a ﬁrst step in this direction [84,85].
All of these technologies are required for MI and BI.
While some of the technologies, such as probabilistic
expert reasoning, standards development and vocabulary
development, are mainly developed inMI, they are of use
in BI. In turn, BI has developed other technologies, such
as database integration and automatic annotation, that
can be used by medical informaticists. The middle part of
Fig. 2 shows technologies that have received a lot of
attention because they are (or will be) required in both
MI and BI. Genomic medicine is expected to use such
technologies increasingly to improve and enhance health
care, including personalized therapies, preventive medi-
cine and molecular medicine. Table 1 shows a summary
of the 18 priorities proposed for an R&D agenda in MI,
BI, and BMI regarding applications for functional
genomics, individualized health care and genomic medi-
cine as well as their priorities for future programs and
institutional actions.
Table 1 shows below a summary of the 18 priorities
proposed by the BIOINFOMED team for a R&D
agenda in MI, BI, and BMI, regarding applications in
functional genomics, individualized health care, and
genomic medicine, and their priorities for future pro-
grams and institutional actions.
Table 1
Summary of the research priorities proposed by the BIOINFOMED study
Barriers Proposed solution Prioritya Riskb
Enabling technologies
High computational and data management
requirements
Grid technologies High Low
Strong privacy issues associated to the nature
of genetic data
Security technologies High High
Need to expand current interoperability standards
for new genetic data infrastructure
Data communication standards High Medium
Heterogeneity of current clinical and genetic sources
and databases. Diﬀerent representation systems
(i.e., ontologies) in medicine and biology.
Ontologies and new approaches to integrate
heterogeneous clinical and genetic databases
High Low
Data and text growing exponentially. New tools
demanded for analysis
Data and text mining High Low
MI in support of functional genomics
Patient care data are not been systematically used
in genomic research.
Phenotype databases suitable for genomic re-
search
High Low
Lack of accepted standards for clinical validation
of results obtained from functional genomics
research
Disease reclassiﬁcation High High
Lack of adequate matching between biomedical
data and pharmaceutical targets
Pharmacogenomics High Medium
BI in support of individualized healthcare
Unavailability of models for including genetic data
into electronic health records
Genetics data model for the EHR Medium Medium
Increased complexity in medical decision making
due to new genetic knowledge
Clinical guidelines and decision making using
genetic information
Medium Medium
Scarce and non-uniform geographic distribution
of clinical genetics specialists and resources
Telegenetics High Low
Methods needed for stratifying patients by
genetic proﬁles in the context of clinical research
New methods and information platforms to
manage genetic data in clinical research
High Medium
Lack of interoperable devices to collect genetic
data and include them in clinical information systems
Point-of care data acquisition systems Medium Medium
Complexity in characterising genomic and phenotypic
microbial diversity related to infectious diseases
Microbial genomics Medium Low
BMI in support of genomic medicine
Lack of high resolution systems to correlate
anatomical structures to physiological
and genetic mechanisms
Molecular and functional imaging Medium Low
Lack of uniﬁed approaches to understanding
and modelling the human body and human diseases.
Modelling and simulation Medium Medium
Linking environmental and lifestyle information
to genetic and clinical data
Populational repositories High Low
Narrow view of genetics and genomics in health
professionals and patients
e-Learning High High
aThe priorities and risks arise from the results obtained from the questionnaires sent to the experts and the subsequent debates and discussions
among them.
bRisk refers to the risk of failure to deliver results.
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In this paper, we have presented the results of the
BIOINFOMED study, carried out by research groups
from three diﬀerent European centers and 30 experts in
BMI and related areas. From the responses given to a
preliminary questionnaire and two expert meetings
carried out with support from the European Commis-
sion to discuss the contents of early drafts, a White
Paper was elaborated. It has been presented here in a
summarized version.The success of the Human Genome Project (http://
www.genome.gov/, http://www.ornl.gov/TechResources/
Human_Genome/home.html) promises to introduce
signiﬁcant advances and challenges in biomedical re-
search and practice. Applications of technologies such
as microarrays are routinely used in many biomedical
research settings, but some innovative approaches are
still needed to change signiﬁcantly current practices
beyond laboratory tests or preventive plans. In this re-
gard, BMI can contribute to accelerate this process by
bringing computerized methods to collect, integrate and
40 F. Martin-Sanchez et al. / Journal of Biomedical Informatics 37 (2004) 30–42analyse combined clinical and genomic data, informa-
tion, and knowledge.
The proposed agenda developed within the BIO-
INFOMED study intends to provide diﬀerent clues and
directions to advance research in BMI, leading to new
approaches and achievements in both functional ge-
nomics and genomic medicine. The development and
implementation of the research priorities and the en-
abling technologies described in this paper would be
facilitated and achieved by collaborative eﬀorts between
MI and BI. The members of the BIOINFOMED study
believe that such interaction will lead to a synergy and
signiﬁcant developments in the new area of Biomedical
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